Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia
Not Applicable
Recruiting
- Conditions
- egionella pneumonia
- Registration Number
- JPRN-UMIN000049139
- Lead Sponsor
- Ohara Healthcare Foundation, Kurashiki Central Hospital, Department of Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Patients treated with antibiotics other than lascufloxacin.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. 30-day mortality 2. In-hospital mortality
- Secondary Outcome Measures
Name Time Method 1. Duration of admission 2. Pneumonia recurrence requiring antibiotic therapy 3. Time to defervescence from start of lascufloxacin (Defervescence was defined in days after the first 24 hours from less than 37.8 degree Celsius or less than 37.0 degree Celsius) 4. Intensive care unit admission, ventilatory support and vasopressor use due to exacerbation of pneumonia 5. Adverse drug effects